中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

19 records (took 0.022 seconds)

    COLLAGEN-BINDING ADHESIN FROM STAPHYLOCOCCUS EPIDERMIDIS AND METHOD OF USE
    4.
    发明申请
    COLLAGEN-BINDING ADHESIN FROM STAPHYLOCOCCUS EPIDERMIDIS AND METHOD OF USE 审中-公开
    胶原蛋白结合胶原蛋白与胶原蛋白的结合及使用方法

    公开(公告)号：WO2002074324A1

    公开(公告)日：2002-09-26

    申请号：PCT/US2002/007807

    申请日：2002-03-15

    Applicant: THE TEXAS A & M UNIVERSITY SYSTEM

    Inventor： HOOK, Magnus ,  BOWDEN, Maria

    IPC: A61K38/00

    CPC classification number: A61K39/085 ,  A61K38/465 ,  A61K2039/505 ,  C07K16/1271 ,  C07K16/40 ,  G01N33/56938

    Abstract: An Isolated lipase, designated GehD , from S. epidermidis has now been found to bind to collagen, and thus this protein may be used in methods of preventing or treating staphylococcal infections. The invention contemplates the use of compositions including GehD, vaccines containing GehD, and antibodies that can recognize GehD, and these are advantageously used with human or animal patients which may be susceptible to staphylococcal disease. In addition, medical instruments or biological implants can be treated using the collagen-binding protein of the invention in order to reduce or eliminate the possibility of their becoming infected or further spreading a staphylococcal infection.

    Abstract translation: 来自i的分离的脂肪酶，指定为GehD 。 已经发现表皮细胞与胶原蛋白结合，因此该蛋白质可用于预防或治疗葡萄球菌感染的方法中。 本发明考虑使用包含GehD，含有GehD的疫苗和可以识别GehD的抗体的组合物，并且它们有利地与可能对葡萄球菌病易感的人或动物患者一起使用。 此外，可以使用本发明的胶原结合蛋白来治疗医疗器械或生物植入物，以减少或消除其变得感染或进一步扩散葡萄球菌感染的可能性。

    ANTIBODIES RECOGNIZING A HIGHLY EXPRESSED PUTATIVE ANTIGEN OF CA-MRSA AND METHODS OF USE
    7.
    发明申请
    ANTIBODIES RECOGNIZING A HIGHLY EXPRESSED PUTATIVE ANTIGEN OF CA-MRSA AND METHODS OF USE 审中-公开
    识别CA-MRSA的高表达的抗原抗体的抗体及其使用方法

    公开(公告)号：WO2007100580A2

    公开(公告)日：2007-09-07

    申请号：PCT/US2007/004497

    申请日：2007-02-22

    Applicant: THE TEXAS A & M UNIVERSITY SYSTEM ,  HOOK, Magnus ,  LABANDEIRA-REY, Maria ,  BOWDEN, M., Gabriela

    Inventor： HOOK, Magnus ,  LABANDEIRA-REY, Maria ,  BOWDEN, M., Gabriela

    IPC: A61K39/395

    CPC classification number: C07K14/31 ,  A61K39/00

    Abstract: The present invention provides MSCRAMM® proteins from S. aureus which are putative highly-expressed antigens from methicillin-resistant S. aureus, including communit -associated MRSA (CA-MRSA), and these antigens can thus be utilized in methods of generating antibodies capable of binding these antigens which can be useful in methods of treating or preventing infection from MRSA. The present invention is directed to these proteins, antibodies capable of binding these proteins, methods of generating said antibodies, nucleic acids coding for said proteins, and pharmaceutical compositions or vaccines which include the proteins or antibodies of the present invention in combination with a pharmaceutically acceptable vehicle, carrier or excipient.

    Abstract translation: 本发明提供来自金黄色葡萄球菌的MSCRAMM蛋白，其是来自耐甲氧西林金黄色葡萄球菌的推定的高度表达的抗原，包括与社区相关的MRSA（CA-MRSA），因此这些抗原可用于产生抗体的方法 可以用于治疗或预防MRSA感染的方法中的这些抗原。 本发明涉及这些蛋白质，能够结合这些蛋白质的抗体，产生所述抗体的方法，编码所述蛋白质的核酸，以及药物组合物或疫苗，其包括本发明的蛋白质或抗体与药学上可接受的组合 车辆，载体或赋形剂。

    STAPHYLOCOCCUS AUREUS EFB PROTEIN AND C3 BINDING REGION WHICH INHIBIT COMPLEMENT ACTIVATION
    8.
    发明申请
    STAPHYLOCOCCUS AUREUS EFB PROTEIN AND C3 BINDING REGION WHICH INHIBIT COMPLEMENT ACTIVATION 审中-公开
    维生素A类蛋白质EFB蛋白和C3结合区域，禁止补体活化

    公开(公告)号：WO2004094600A2

    公开(公告)日：2004-11-04

    申请号：PCT/US2004/011949

    申请日：2004-04-16

    Applicant: THE TEXAS A & M UNIVERSITY SYSTEM ,  BROWN, Eric ,  LEE, Lawrence ,  HOOK, Magnus

    Inventor： BROWN, Eric ,  LEE, Lawrence ,  HOOK, Magnus

    IPC: C12N

    CPC classification number: C07K14/31 ,  A61K39/00 ,  A61K2039/505 ,  G01N33/564 ,  G01N33/56938

    Abstract: The Efb protein from Staphylococcus aureus has now been shown to have the ability to bind to the C3 protein which is a crucial component in the activation of complement, and a specific C3 binding region has been located at the C-terminal end of the Efb protein. Isolated proteins and protein fragments containing the Efb protein C3 binding region are thus provided which have complement inhibiting activity, and these proteins and fragments are particularly useful in therapeutic methods wherein the inhibition of complement is desirable, such as in the treatment of hemolytic anemia, the prevention of graft or implant rejection, and to alleviate complement activation that is associated with kidney dialysis methods such as hemodialysis.

    Abstract translation: 来自金黄色葡萄球菌的Efb蛋白质已被证明具有结合C3蛋白的能力，C3蛋白是补体活化中的关键成分，特异性C3结合区位于Efb蛋白的C末端 。 因此提供了含有Efb蛋白C 3结合区的分离的蛋白质和蛋白质片段，其具有补体抑制活性，并且这些蛋白质和片段特别可用于其中需要补体抑制的治疗方法，例如在溶血性贫血的治疗中， 预防移植物或植入物排斥，以及减轻与肾透析方法如血液透析相关的补体活化。

    TARGETING OF LIGAND BINDING SITES IN CLFA
    10.
    发明申请
    TARGETING OF LIGAND BINDING SITES IN CLFA 审中-公开
    在CLFA中定位配体结合位点

    公开(公告)号：WO2017079681A1

    公开(公告)日：2017-05-11

    申请号：PCT/US2016/060709

    申请日：2016-11-04

    Applicant: THE TEXAS A&M UNIVERSITY SYSTEM

    Inventor： GANESH, Vannakambadi, K. ,  HOOK, Magnus

    IPC: A61K39/085 ,  A61K39/40 ,  A61P31/04 ,  C07K16/12 ,  C12N15/13

    CPC classification number: C07K16/1271 ,  C07K2299/00 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/92

    Abstract: The present invention provides methods and compositions to reduce binding of fibrinogen to the ClfA in a gram positive bacterial infections using monoclonal antibody, a polyclonal antibody, an antigen-binding antibody fragment or a composition that specifically binds to a portion of ClfA with the sequence of SEQ ID No: 15, SEQ ID NO: 16, SEQ ID NO: 17, and SEQ ID NO: 18.

    Abstract translation: 本发明提供了使用单克隆抗体，多克隆抗体，抗原结合抗体片段或特异性结合至抗体结合抗体片段的组合物减少纤维蛋白原在格兰氏阳性细菌感染中与ClfA结合的方法和组合物 具有序列SEQ ID No：15，SEQ ID NO：16，SEQ ID NO：17和SEQ ID NO：18的部分ClfA。

Patent Agency Ranking